Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.

Article Details

Citation

Copy to clipboard

de Paulis T

Drug evaluation: PRX-00023, a selective 5-HT1A receptor agonist for depression.

Curr Opin Investig Drugs. 2007 Jan;8(1):78-86.

PubMed ID

17263189 [ View in PubMed

]

Abstract

EPIX Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) is developing PRX-00023, an oral aryl piperazine 5-HT1A agonist, for the potential treatment of depression. While initially in development for generalized anxiety disorder, EPIX is now only focusing on the development of PRX-00023 for depression. In November 2006, EPIX reported that it planned to initiate a phase II trial in patients with depression in the first half of 2007.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Naluzotan	5-hydroxytryptamine receptor 1A	Protein	Humans	Unknown	Agonist	Details